[en] [en] OBJECTIVE: Aggregation of human islet amyloid polypeptide (hIAPP), a β-cell secretory product, leads to islet amyloid deposition, islet inflammation and β-cell loss in type 2 diabetes (T2D), but the mechanisms that underlie this process are incompletely understood. Receptor interacting protein kinase 3 (RIPK3) is a pro-death signaling molecule that has recently been implicated in amyloid-associated brain pathology and β-cell cytotoxicity. Here, we evaluated the role of RIPK3 in amyloid-induced β-cell loss using a humanized mouse model of T2D that expresses hIAPP and is prone to islet amyloid formation.
METHODS: We quantified amyloid deposition, cell death and caspase 3/7 activity in islets isolated from WT, Ripk3-/-, hIAPP and hIAPP; Ripk3-/- mice in real time, and evaluated hIAPP-stimulated inflammation in WT and Ripk3-/- bone marrow derived macrophages (BMDMs) in vitro. We also characterized the role of RIPK3 in glucose stimulated insulin secretion (GSIS) in vitro and in vivo. Finally, we examined the role of RIPK3 in high fat diet (HFD)-induced islet amyloid deposition, β-cell loss and glucose homeostasis in vivo.
RESULTS: We found that amyloid-prone hIAPP mouse islets exhibited increased cell death and caspase 3/7 activity compared to amyloid-free WT islets in vitro, and this was associated with increased RIPK3 expression. hIAPP; Ripk3-/- islets were protected from amyloid-induced cell death compared to hIAPP islets in vitro, although amyloid deposition and caspase 3/7 activity were not different between genotypes. We observed that macrophages are a source of Ripk3 expression in isolated islets, and that Ripk3-/- BMDMs were protected from hIAPP-stimulated inflammatory gene expression (Tnf, Il1b, Nos2). Following 52 weeks of HFD feeding, islet amyloid-prone hIAPP mice exhibited impaired glucose tolerance and decreased β-cell area compared to WT mice in vivo, whereas hIAPP; Ripk3-/- mice were protected from these impairments.
CONCLUSIONS: In conclusion, loss of RIPK3 protects from amyloid-induced inflammation and islet cell death in vitro and amyloid-induced β-cell loss and glucose intolerance in vivo. We propose that therapies targeting RIPK3 may reduce islet inflammation and β-cell loss and improve glucose homeostasis in the pathogenesis of T2D.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Mukherjee, Noyonika; Department of Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA
Contreras, Christopher J; Division of Endocrinology, Department of Medicine, Roudebush VA Medical Center and Indiana University School of Medicine, Indianapolis, IN, USA
Lin, Li; Lilly Diabetes Center of Excellence, Indiana Biosciences Research Institute, Indianapolis, IN, USA
Colglazier, Kaitlyn A; Lilly Diabetes Center of Excellence, Indiana Biosciences Research Institute, Indianapolis, IN, USA
Mather, Egan G; Lilly Diabetes Center of Excellence, Indiana Biosciences Research Institute, Indianapolis, IN, USA
Kalwat, Michael A; Lilly Diabetes Center of Excellence, Indiana Biosciences Research Institute, Indianapolis, IN, USA
Esser, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and the University of Washington, Seattle, WA, USA
Kahn, Steven E; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and the University of Washington, Seattle, WA, USA
Templin, Andrew T ; Department of Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA, Division of Endocrinology, Department of Medicine, Roudebush VA Medical Center and Indiana University School of Medicine, Indianapolis, IN, USA, Lilly Diabetes Center of Excellence, Indiana Biosciences Research Institute, Indianapolis, IN, USA, Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: templin@iu.edu
Language :
English
Title :
RIPK3 promotes islet amyloid-induced β-cell loss and glucose intolerance in a humanized mouse model of type 2 diabetes.
Kahn, S.E., The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:9 (2001 Sep), 4047–4058.
Cho, N.H., Shaw, J.E., Karuranga, S., Huang, Y., da Rocha Fernandes, J.D., Ohlrogge, A.W., et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138 (2018 Apr 1), 271–281.
Kahn, S.E., Andrikopoulos, S., Verchere, C.B., Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:2 (1999 Feb 1), 241–253.
Jurgens, C.A., Toukatly, M.N., Fligner, C.L., Udayasankar, J., Subramanian, S.L., Zraika, S., et al. β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178:6 (2011 Jun 1), 2632–2640.
Meier, D.T., Morcos, M., Samarasekera, T., Zraika, S., Hull, R.L., Kahn, S.E., Islet amyloid formation is an important determinant for inducing islet inflammation in high-fat-fed human IAPP transgenic mice. Diabetologia 57:9 (2014 Sep), 1884–1888.
Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A., Butler, P.C., Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:1 (2003 Jan), 102–110.
Kahn, S.E., D'Alessio, D.A., Schwartz, M.W., Fujimoto, W.Y., Ensinck, J.W., Taborsky, G.J. Jr., et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:5 (1990 May 1), 634–638.
Westermark, P., Engström, U., Johnson, K.H., Westermark, G.T., Betsholtz, C., Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:13 (1990 Jul), 5036–5040.
Lorenzo, A., Razzaboni, B., Weir, G.C., Yankner, B.A., Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368:6473 (1994 Apr), 756–760.
Verchere, C.B., D'Alessio, D.A., Palmiter, R.D., Weir, G.C., Bonner-Weir, S., Baskin, D.G., et al. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:8 (1996 Apr 16), 3492–3496.
Janson, J., Soeller, W.C., Roche, P.C., Nelson, R.T., Torchia, A.J., Kreutter, D.K., et al. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:14 (1996 Jul 9), 7283–7288.
Lopes, D.H.J., Colin, C., Degaki, T.L., Sousa, A.C.V. de, Vieira, M.N.N., Sebollela, A., et al. Amyloidogenicity and cytotoxicity of recombinant mature human islet amyloid polypeptide (hIAPP). J Biol Chem 279:41 (2004 Oct 8), 42803–42810.
Birol, M., Kumar, S., Rhoades, E., Miranker, A.D., Conformational switching within dynamic oligomers underpins toxic gain-of-function by diabetes-associated amyloid. Nat Commun, 9(1), 2018 Apr 3, 1312.
Janson, J., Ashley, R.H., Harrison, D., McIntyre, S., Butler, P.C., The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:3 (1999 Mar 1), 491–498.
Abedini, A., Cao, P., Plesner, A., Zhang, J., He, M., Derk, J., et al. RAGE binds preamyloid IAPP intermediates and mediates pancreatic β cell proteotoxicity. J Clin Investig 128:2 (2018 Feb 1), 682–698.
Abedini, A., Derk, J., Schmidt, A.M., The receptor for advanced glycation endproducts is a mediator of toxicity by IAPP and other proteotoxic aggregates: establishing and exploiting common ground for novel amyloidosis therapies. Protein Sci 27:7 (2018 Jul), 1166–1180.
Templin, A.T., Mellati, M., Meier, D.T., Esser, N., Hogan, M.F., Castillo, J.J., et al. Low concentration IL-1β promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro. Diabetologia 63:11 (2020 Nov), 2385–2395.
Caccamo, A., Branca, C., Piras, I.S., Ferreira, E., Huentelman, M.J., Liang, W.S., et al. Necroptosis activation in Alzheimer's disease. Nat Neurosci 20:9 (2017 Sep), 1236–1246.
Zou, C., Mifflin, L., Hu, Z., Zhang, T., Shan, B., Wang, H., et al. Reduction of mNAT1/hNAT2 contributes to cerebral endothelial necroptosis and Aβ accumulation in Alzheimer's Disease. Cell Rep, 33(10), 2020 Dec 8, 108447.
Kumar, S., Budhathoki, S., Oliveira, C.B., Kahle, A.D., Calhan, O.Y., Lukens, J.R., et al. Role of the caspase-8/RIPK3 axis in Alzheimer's disease pathogenesis and Aβ-induced NLRP3 inflammasome activation. JCI Insight, 8(3), 2023 Feb 8, e157433.
Preston, S.P., Stutz, M.D., Allison, C.C., Nachbur, U., Gouil, Q., Tran, B.M., et al. Epigenetic silencing of RIPK3 in hepatocytes prevents MLKL-mediated necroptosis from contributing to liver pathologies. Gastroenterology 163:6 (2022 Dec), 1643–1657.e14.
Moriwaki, K., Bertin, J., Gough, P.J., Chan, F.K.M., A RIPK3-Caspase 8 complex mediates atypical pro-IL-1β processing. J Immunol 194:4 (2015 Feb 15), 1938–1944.
Yang, B., Maddison, L.A., Zaborska, K.E., Dai, C., Yin, L., Tang, Z., et al. RIPK3-mediated inflammation is a conserved β cell response to ER stress. Sci Adv, 6(51), 2020, eabd7272.
Contreras, C.J., Mukherjee, N., Branco, R.C.S., Lin, L., Hogan, M.F., Cai, E.P., et al. RIPK1 and RIPK3 regulate TNFα-induced β-cell death in concert with caspase activity. Mol Metab, 65, 2022 Nov 1, 101582.
Moriwaki, K., Chan, F.K.M., Necroptosis-independent signaling by the RIP kinases in inflammation. Cell Mol Life Sci 73:11–12 (2016 Jun 1), 2325–2334.
Orozco, S.L., Daniels, B.P., Yatim, N., Messmer, M.N., Quarato, G., Chen-Harris, H., et al. RIPK3 activation leads to cytokine synthesis that continues after loss of cell membrane integrity. Cell Rep 28:9 (2019 Aug 27), 2275–2287.e5.
Newton, K., Dugger, D.L., Wickliffe, K.E., Kapoor, N., Almagro, M.C. de, Vucic, D., et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 343:6177 (2014 Mar 21), 1357–1360.
Dondelinger, Y., Aguileta, M.A., Goossens, V., Dubuisson, C., Grootjans, S., Dejardin, E., et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ 20:10 (2013 Oct), 1381–1392.
Rodriguez, D.A., Weinlich, R., Brown, S., Guy, C., Fitzgerald, P., Dillon, C.P., et al. Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. Cell Death Differ 23:1 (2016 Jan), 76–88.
Hull, R.L., Andrikopoulos, S., Verchere, C.B., Vidal, J., Wang, F., Cnop, M., et al. Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52:2 (2003 Feb), 372–379.
Zraika, S., Hull, R.L., Udayasankar, J., Utzschneider, K.M., Tong, J., Gerchman, F., et al. Glucose- and time-dependence of islet amyloid formation in vitro. Biochem Biophys Res Commun 354:1 (2007 Mar 2), 234–239.
Templin, A.T., Mellati, M., Soininen, R., Hogan, M.F., Esser, N., Castillo, J.J., et al. Loss of perlecan heparan sulfate glycosaminoglycans lowers body weight and decreases islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Protein Eng Des Sel 32:2 (2019 Dec 13), 95–102.
Templin, A.T., Meier, D.T., Willard, J.R., Wolden-Hanson, T., Conway, K., Lin, Y.G., et al. Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice. Diabetologia 61:10 (2018 Oct), 2215–2224.
D'Alessio, D.A., Verchere, C.B., Kahn, S.E., Hoagland, V., Baskin, D.G., Palmiter, R.D., et al. Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:12 (1994 Dec), 1457–1461.
Wang, F., Hull, R.L., Vidal, J., Cnop, M., Kahn, S.E., Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:11 (2001 Nov 1), 2514–2520.
Meier, D.T., Entrup, L., Templin, A.T., Hogan, M.F., Samarasekera, T., Zraika, S., et al. Determination of optimal sample size for quantification of β-cell area, amyloid area and β-cell apoptosis in isolated islets. J Histochem Cytochem 63:8 (2015 Aug), 663–673.
Bussière, T., Bard, F., Barbour, R., Grajeda, H., Guido, T., Khan, K., et al. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance. Am J Pathol 165:3 (2004 Sep), 987–995.
Grootjans, S., Hassannia, B., Delrue, I., Goossens, V., Wiernicki, B., Dondelinger, Y., et al. A real-time fluorometric method for the simultaneous detection of cell death type and rate. Nat Protoc 11:8 (2016 Aug), 1444–1454.
Opie, E.L., The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans. J Exp Med 5:5 (1901 Mar 25), 527–540.
Maclean, N., Ogilvie, R.F., Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes 4:5 (1955 Oct), 367–376.
Park, Y.J., Woo, M., Kieffer, T.J., Hakem, R., Safikhan, N., Yang, F., et al. The role of caspase-8 in amyloid-induced beta cell death in human and mouse islets. Diabetologia 57:4 (2014 Apr), 765–775.
Li, H., Khosrow-Khavar, F., Speck, M., Kieffer, T., Woo, M., Marzban, L., Suppression of caspase-3 activation protects primary islet β-cells from the cytotoxic effects of human islet amyloid polypeptide. Can J Diabetes, 32(4), 2008 Jan 1, 302.
Kaiser, W.J., Upton, J.W., Long, A.B., Livingston-Rosanoff, D., Daley, L.P., Hakem, R., et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471:7338 (2011 Mar 17), 368–372.
Abdelhady, R., Younis, N.S., Ali, O., Shehata, S., Sayed, R.H., Nadeem, R.I., Cognitive enhancing effects of pazopanib in D-galactose/ovariectomized Alzheimer's rat model: insights into the role of RIPK1/RIPK3/MLKL necroptosis signaling pathway. Inflammopharmacology 31:5 (2023 Oct 1), 2719–2729.
Wong, W.W.L., Vince, J.E., Lalaoui, N., Lawlor, K.E., Chau, D., Bankovacki, A., et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood 123:16 (2014 Apr 17), 2562–2572.
Moriwaki, K., Balaji, S., McQuade, T., Malhotra, N., Kang, J., Chan, F.K.M., The necroptosis adaptor RIPK3 promotes injury-induced cytokine expression and tissue repair. Immunity 41:4 (2014 Oct 16), 567–578.
Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 11:10 (2010 Oct), 897–904.
Butcher, M.J., Hallinger, D., Garcia, E., Machida, Y., Chakrabarti, S., Nadler, J., et al. Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes. Diabetologia 57:3 (2014 Mar), 491–501.
Wu, L., Zhang, X., Zheng, L., Zhao, H., Yan, G., Zhang, Q., et al. RIPK3 orchestrates fatty acid metabolism in tumor-associated macrophages and hepatocarcinogenesis. Cancer Immunol Res 8:5 (2020 May 1), 710–721.
Roychowdhury, S., McCullough, R.L., Sanz-Garcia, C., Saikia, P., Alkhouri, N., Matloob, A., et al. Receptor interacting protein 3 protects mice from high-fat diet-induced liver injury. Hepatol 64:5 (2016 Nov), 1518–1533.
Newton, K., Sun, X., Dixit, V.M., Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and toll-like receptors 2 and 4. Mol Cell Biol 24:4 (2004 Feb), 1464–1469.
Andrikopoulos, S., Massa, C.M., Aston-Mourney, K., Funkat, A., Fam, B.C., Hull, R.L., et al. Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet. J Endocrinol 187:1 (2005 Oct), 45–53.
Zhang, D.W., Shao, J., Lin, J., Zhang, N., Lu, B.J., Lin, S.C., et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325:5938 (2009 Jul 17), 332–336.
Cabrera, O., Berman, D.M., Kenyon, N.S., Ricordi, C., Berggren, P.O., Caicedo, A., The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A 103:7 (2006 Feb 14), 2334–2339.
Liu, S., Joshi, K., Denning, M.F., Zhang, J., RIPK3 signaling and its role in the pathogenesis of cancers. Cell Mol Life Sci 78:23 (2021 Dec 1), 7199–7217.
Conev, N.V., Dimitrova, E.G., Bogdanova, M.K., Kashlov, Y.K., Chaushev, B.G., Radanova, M.A., et al. RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer. Clin Investig Med 42:1 (2019 Mar 23), E31–E38.
Martin-Sanchez, D., Guerrero-Mauvecin, J., Fontecha-Barriuso, M., Mendez-Barbero, N., Saiz, M.L., Lopez-Diaz, A.M., et al. Bone marrow–derived RIPK3 mediates kidney inflammation in acute kidney injury. J Am Soc Nephrol 33:2 (2022 Feb), 357–373.
Sureshbabu, A., Patino, E., Ma, K.C., Laursen, K., Finkelsztein, E.J., Akchurin, O., et al. RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial dysfunction. JCI Insight, 3(11), 2018, e98411.
Oñate, M., Catenaccio, A., Salvadores, N., Saquel, C., Martinez, A., Moreno-Gonzalez, I., et al. The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease. Cell Death Differ 27:4 (2020 Apr), 1169–1185.
